| Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation. | Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation.
Chen Y, Zhuo R, Sun L, Tao Y, Li G, Zhu F, Xu Y, Wang J, Li Z, Yu J, Yin H, Wu D, Li X, Fang F, Xie Y, Hu Y, Wang H, Yang C, Shi L, Wang X, Zhang Z, Pan J., | 10/9/2024 |
| Novel hypermorphic variants in IRF2BP2 identified in patients with common variable immunodeficiency and autoimmunity. | Novel hypermorphic variants in IRF2BP2 identified in patients with common variable immunodeficiency and autoimmunity.
Anim M, Sogkas G, Camacho-Ordonez N, Schmidt G, Elsayed A, Proietti M, Witte T, Grimbacher B, Atschekzei F. | 08/22/2024 |
| Novel frameshift variants expand the map of the genetic defects in IRF2BP2. | Novel frameshift variants expand the map of the genetic defects in IRF2BP2.
García-Aznar JM, Maneiro Pampín E, García Ramos M, Acuña Pérez MJ, Paz Gandiaga N, Minguell Domingo L, Calavia O, Soler-Palacin P, Colobran R, Novoa Bolívar EM, Ocejo Vinyals JG., Free PMC Article | 10/30/2023 |
| LncRNA ATP1A1-AS1 inhibits cell proliferation and promotes cell apoptosis in thyroid carcinoma by regulating the miR-620/IRF2BP2 axis. | LncRNA ATP1A1-AS1 inhibits cell proliferation and promotes cell apoptosis in thyroid carcinoma by regulating the miR-620/IRF2BP2 axis.
Jia J, Liu Y, Yang X, Wu Z, Xu X, Kang F, Liu Y. | 01/14/2023 |
| A novel IRF2BP2::CDX2 Gene fusion in digital intravascular myoepithelioma of soft tissue: An enigma! | A novel IRF2BP2::CDX2 Gene fusion in digital intravascular myoepithelioma of soft tissue: An enigma!
Patton A, Speeckaert A, Zeltman M, Cui X, Oghumu S, Iwenofu OH., Free PMC Article | 01/14/2023 |
| Down-regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor. | Down-regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor.
Yao Y, Wang Y, Li L, Xiang X, Li J, Chen J, Liu Z, Huang S, Xiong J, Deng J., Free PMC Article | 10/24/2020 |
| The expression of interferon regulatory protein 2-binding protein 2 (IRF2BP2), a regulator of KLF2, suppressed osteoclast differentiation and enhanced osteoblast differentiation and function. | The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation.
Kim I, Kim JH, Kim K, Seong S, Kim N., Free PMC Article | 02/8/2020 |
| findings showed that the IRF2BP2-RARalpha fusion has the capacity to transform primary hematopoietic stem/progenitor cells and induced an ATRA-responsive acute promyelocytic leukemia (APL); this provides further evidence that formation of RARA fusion genes represent disease-defining mutations in APL pathogenesis | The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.
Jovanovic JV, Chillón MC, Vincent-Fabert C, Dillon R, Voisset E, Gutiérrez NC, Sanz RG, Lopez AA, Morgan YG, Lok J, Solomon E, Duprez E, Díaz MG, Grimwade D. | 09/7/2019 |
| A novel IRFBP2 mutation was identified in a family with autosomal dominant CVID. Transduction experiments suggest that the mutant protein has an effect on B-cell differentiation and is likely a monogenic cause of the family's CVID phenotype. | Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder.
Keller MD, Pandey R, Li D, Glessner J, Tian L, Henrickson SE, Chinn IK, Monaco-Shawver L, Heimall J, Hou C, Otieno FG, Jyonouchi S, Calabrese L, van Montfrans J, Orange JS, Hakonarson H., Free PMC Article | 06/24/2017 |
| ETO2 and IRF2BP2 interacting with the NCOR1/SMRT co-repressor complex, suppresses the expression of erythroid genes until erythroid differentiation. | Control of developmentally primed erythroid genes by combinatorial co-repressor actions.
Stadhouders R, Cico A, Stephen T, Thongjuea S, Kolovos P, Baymaz HI, Yu X, Demmers J, Bezstarosti K, Maas A, Barroca V, Kockx C, Ozgur Z, van Ijcken W, Arcangeli ML, Andrieu-Soler C, Lenhard B, Grosveld F, Soler E., Free PMC Article | 07/2/2016 |
| A deletion variant that lowers IRF2BP2 expression predisposes to coronary artery disease in humans. | IRF2BP2 Reduces Macrophage Inflammation and Susceptibility to Atherosclerosis.
Chen HH, Keyhanian K, Zhou X, Vilmundarson RO, Almontashiri NA, Cruz SA, Pandey NR, Lerma Yap N, Ho T, Stewart CA, Huang H, Hari A, Geoffrion M, McPherson R, Rayner KJ, Stewart AF. | 01/2/2016 |
| analysis of an IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma | Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma.
Nyquist KB, Panagopoulos I, Thorsen J, Haugom L, Gorunova L, Bjerkehagen B, Fosså A, Guriby M, Nome T, Lothe RA, Skotheim RI, Heim S, Micci F., Free PMC Article | 05/25/2013 |
| Nuclear localization of IRF2BP2 depends on phosphorylation near a conserved NLS. Changes in phosphorylation status likely control nucleocytoplasmic localization of IRF2BP2 during muscle differentiation. | Identification of a phosphorylation-dependent nuclear localization motif in interferon regulatory factor 2 binding protein 2.
Teng AC, Al-Montashiri NA, Cheng BL, Lou P, Ozmizrak P, Chen HH, Stewart AF., Free PMC Article | 02/25/2012 |
| results indicate that DIF-1 plays a key role in breast cancer cell survival | Identification of a novel pathway that selectively modulates apoptosis of breast cancer cells.
Tinnikov AA, Yeung KT, Das S, Samuels HH., Free PMC Article | 10/22/2011 |
| Data demonstrate that IRF-2BP2 is a negative regulator of the NFAT1 transcription factor and suggest that NFAT1 repression occurs at the transcriptional level. | Interferon regulatory factor 2 binding protein 2 is a new NFAT1 partner and represses its transcriptional activity.
Carneiro FR, Ramalho-Oliveira R, Mognol GP, Viola JP., Free PMC Article | 10/8/2011 |
| IRF2BP2 is a novel ischemia-induced coactivator of VEGFA expression that may contribute to revascularization of ischemic cardiac and skeletal muscles. | IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression.
Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, Cheng BL, Crowson MG, Burgon PG, Suuronen EJ, Chen HH, Stewart AF, Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, Cheng BL, Crowson MG, Burgon PG, Suuronen EJ, Chen HH, Stewart AF. | 01/8/2011 |
| IRF2BP2 works with TEAD transcription factors to upregulate the expression of VEGFA in skeletal and cardiac muscle. IRF2BP2 protein levels are increased in response to tissue ischemia. | IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression.
Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, Cheng BL, Crowson MG, Burgon PG, Suuronen EJ, Chen HH, Stewart AF, Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, Cheng BL, Crowson MG, Burgon PG, Suuronen EJ, Chen HH, Stewart AF. | 09/20/2010 |
| Identification of IRF-2 binding protein 1 and IRF-2 binding protein 2 as co-repressor molecules for interferon regulatory factor-2. | Identification of novel co-repressor molecules for Interferon Regulatory Factor-2.
Childs KS, Goodbourn S., Free PMC Article | 01/21/2010 |